ConductScience.org, home

Comparison · NCT03282799-a32c734b

Standard Dose Etonogestrel Implant vs Increased Dose Etonogestrel Implant: Proportion of Participants That Ovulate During Month 3

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Standard Dose Etonogestrel Implant vs Increased Dose Etonogestrel Implant: Proportion of Participants That Ovulate During Month 3. Trial comparisons, record NCT03282799-a32c734b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03282799-a32c734b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3140.1860.48wilson
Risk in group 2000.0964wilson
Risk difference, group 1 minus group 20.3140.1530.48newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Standard Dose Etonogestrel Implant than on Increased Dose Etonogestrel Implant3.182.086.52from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Standard Dose Etonogestrel ImplantSingle 68 mg etonogestrel implant~etonogestrel implant: The etonogestrel implant is an contraceptive implant that is placed into the upper arm.1135OG000
Group 2Increased Dose Etonogestrel ImplantTwo 68 mg (136 mg total) etonogestrel implants~etonogestrel implant: The etonogestrel implant is an contraceptive implant that is placed into the upper arm.036OG001

Outcome

Type
PRIMARY
Title
Proportion of Participants That Ovulate During Month 3
Description
Proportion of participants that experience at least one ovulation during month 3 of etonogestrel implant use. Serum progesterone concentrations are measured weekly during month 3 (weeks 9-12). Ovulation is defined as endogenous progesterone concentrations of \>3 ng/mL.
Time frame
3 months
Population
One participant in the standard dose arm was withdrawn at week 1 of the study due to pregnancy.

Source ClinicalTrials.gov

Trial

Title
Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
NCT number
NCT03282799
Phases
PHASE2
Conditions
HIV/AIDS, Contraception
Interventions
etonogestrel implant
Lead sponsor
Catherine Anne Chappell
Results first posted
2024-09-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03282799-a32c734b